Sign Up Now to Download a Free Research Report on

Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts




Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader.

Pluristem Therapeutics

Pluristem Therapeutics received approval from the Paul-Ehrlich-Institute, a German regulatory body, to expand its phase II clinical trial using PLX-PAD cells in patients suffering from Intermittent Claudication. Shares of the company spiked nearly 7 percent Tuesday.

Going forward ... (see research report)



RESEARCH REPORT ON Download Free Report Now


Preview Pages of Actual Equity Report

Download Adobe Reader Having problems viewing PDF files? Download Adobe Reader. Research Report on    Research Report on    Research Report on    

Research Report on    Research Report on    Research Report on